Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment

Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D 3 dopamine receptor over D 2 dopamine receptor

(2021) Patrick Appiah‐Kubi et al.   JOURNAL OF MOLECULAR RECOGNITION

Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders

(2021) Béla Kiss et al.   Biomolecules

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder

(2021) Viktor Román et al.   PSYCHOPHARMACOLOGY

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data

(2020) Balázs Szatmári et al.   Frontiers in Psychiatry

Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data

(2020) Stephen M. Stahl et al.   Therapeutic Advances in Psychopharmacology

Genetic and Epigenetic Etiology Underlying Autism Spectrum Disorder

(2020) Sang Hoon Yoon et al.   Journal of Clinical Medicine

P-cresol Alters Brain Dopamine Metabolism and Exacerbates Autism-Like Behaviors in the BTBR Mouse

(2020) Tiziana Pascucci et al.   Brain Sciences

The Neurochemistry of Autism

(2020) Rosa Marotta et al.   Brain Sciences

Altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism

(2020) Owen Y. Chao et al.   Molecular Brain

Autism Spectrum Disorder and Schizophrenia Are Better Differentiated by Positive Symptoms Than Negative Symptoms

(2020) Dominic A. Trevisan et al.   Frontiers in Psychiatry

Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist

(2020) Cristina Cosi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs

(2020) Mark J. Millan et al.   NEUROPHARMACOLOGY

Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors

(2019) Gabriella E. DiCarlo et al.   JOURNAL OF CLINICAL INVESTIGATION

Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

(2019) Amanda Krogmann et al.   CNS SPECTRUMS

The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens

(2019) Mei Huang et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia

(2019) Saori Takeuchi et al.   NEUROCHEMISTRY INTERNATIONAL

Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review

(2019) Ethan A. Poweleit et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia

(2018) Marc Cantillon et al.   CTS-Clinical and Translational Science

Neuropsychiatric disease–associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes

(2018) Freja Herborg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder

(2018) Nermin Eissa et al.   Frontiers in Neuroscience

A fresh look at cortical dopamine D2 receptor expressing neurons

(2018) Clémentine Quintana et al.   PHARMACOLOGICAL RESEARCH

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology

(2017) Oliver D Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

(2017) György Németh et al.   LANCET

Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder

(2017) Marc Cantillon et al.   SCHIZOPHRENIA RESEARCH

Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review

(2016) K. Jobski et al.   ACTA PSYCHIATRICA SCANDINAVICA

The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia

(2016) David J.G. Watson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder

(2016) Yesie Yoon et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Dopaminergic Neurotransmission in the Nucleus Accumbens Modulates Social Play Behavior in Rats

(2016) Antonia Manduca et al.   NEUROPSYCHOPHARMACOLOGY

The neurobiology of social play and its rewarding value in rats

(2016) Louk J.M.J. Vanderschuren et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

(2016) Ragy R. Girgis et al.   PSYCHOPHARMACOLOGY

Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study

(2016) Marco Lamberti et al.   PEDIATRIC DRUGS

Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony

(2016) Clément E. Lemercier et al.   Frontiers in Pharmacology

DRD3 gene and striatum in autism spectrum disorder

(2015) Wouter G. Staal et al.   BRITISH JOURNAL OF PSYCHIATRY

Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial

(2015) Michael Aman et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Natural Neural Projection Dynamics Underlying Social Behavior

(2014) Lisa A. Gunaydin et al.   CELL

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Autism Spectrum Disorder

(2014) Fred Volkmar et al.   JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

The place of dopamine in the cortico-basal ganglia circuit

(2014) S.N. Haber   NEUROSCIENCE

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

(2014) Gretchen L. Snyder et al.   PSYCHOPHARMACOLOGY

Use of aripiprazole and risperidone in children with autism: Effects of introducing an alternative new patented drug and debuting the first generic drug

(2014) L. Wang et al.   VALUE IN HEALTH

Dopamine D3 receptor as a new pharmacological target for the treatment of depression

(2013) Gian Marco Leggio et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

(2013) S Hong Lee et al.   NATURE GENETICS

Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

(2013) Gerhard Gross et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care

(2013) Macey L. Murray et al.   PSYCHOPHARMACOLOGY

The role of the striatum in social behavior

(2013) Raymundo Báez-Mendoza et al.   Frontiers in Neuroscience

Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

(2012) Gabriel S Dichter et al.   Journal of Neurodevelopmental Disorders

Use of Psychotropic Medication in Children and Adolescents With Autism Spectrum Disorders

(2012) Daniel L. Coury et al.   PEDIATRICS

The social motivation theory of autism

(2012) Coralie Chevallier et al.   TRENDS IN COGNITIVE SCIENCES

Neurotransmitter systems and neurotrophic factors in autism: association study of 37 genes suggests involvement of DDC

(2012) Claudio Toma et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive Behavior

(2011) Pavel Golubchik et al.   CLINICAL NEUROPHARMACOLOGY

Aripiprazole for the treatment of irritability associated with autism

(2011) Cristan Ann Farmer et al.   EXPERT OPINION ON PHARMACOTHERAPY

Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

(2011) David J. G. Watson et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Contribution of SPECT Measurements of D2 and 5-HT2A Occupancy to the Clinical Development of the Antipsychotic SB-773812

(2011) A. M. Catafau et al.   JOURNAL OF NUCLEAR MEDICINE

Human cognitive flexibility depends on dopamine D2 receptor signaling

(2011) Mieke van Holstein et al.   PSYCHOPHARMACOLOGY

Reward processing in autism

(2010) Ashley A. Scott-Van Zeeland et al.   Autism Research

Dopamine in Motivational Control: Rewarding, Aversive, and Alerting

(2010) Ethan S. Bromberg-Martin et al.   NEURON

Psychopharmacology in autism: An update

(2010) Roberto Canitano et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Getting specialized: presynaptic and postsynaptic dopamine D2 receptors

(2009) Claudia De Mei et al.   CURRENT OPINION IN PHARMACOLOGY

Comparison of social cognitive functioning in schizophrenia and high functioning autism: more convergence than divergence

(2009) S. M. Couture et al.   PSYCHOLOGICAL MEDICINE

A Common Variant in DRD3 Receptor Is Associated with Autism Spectrum Disorder

(2008) Mariken de Krom et al.   BIOLOGICAL PSYCHIATRY

Quantitative Analysis of the Expression of Dopamine D1 and D2 Receptors in Pyramidal and GABAergic Neurons of the Rat Prefrontal Cortex

(2008) N. Santana et al.   CEREBRAL CORTEX